Deltex Medical Group plc

AIM:DEMG Stock Report

Market Cap: UK£1.5m

Deltex Medical Group Management

Management criteria checks 4/4

Deltex Medical Group's CEO is Andy Mears, appointed in Jun 2018, has a tenure of 6.58 years. total yearly compensation is £190.50K, comprised of 91.9% salary and 8.1% bonuses, including company stock and options. directly owns 0.61% of the company’s shares, worth £9.33K. The average tenure of the management team and the board of directors is 6.6 years and 6.6 years respectively.

Key information

Andy Mears

Chief executive officer

UK£190.5k

Total compensation

CEO salary percentage91.9%
CEO tenure6.6yrs
CEO ownership0.6%
Management average tenure6.6yrs
Board average tenure6.6yrs

Recent management updates

Here's Why Deltex Medical Group plc's (LON:DEMG) CEO Compensation Is The Least Of Shareholders Concerns

May 02
Here's Why Deltex Medical Group plc's (LON:DEMG) CEO Compensation Is The Least Of Shareholders Concerns

Recent updates

Here's Why Deltex Medical Group plc's (LON:DEMG) CEO Compensation Is The Least Of Shareholders Concerns

May 02
Here's Why Deltex Medical Group plc's (LON:DEMG) CEO Compensation Is The Least Of Shareholders Concerns

Is Deltex Medical Group (LON:DEMG) A Risky Investment?

Sep 22
Is Deltex Medical Group (LON:DEMG) A Risky Investment?

Is Deltex Medical Group (LON:DEMG) A Risky Investment?

Apr 22
Is Deltex Medical Group (LON:DEMG) A Risky Investment?

Deltex Medical Group (LON:DEMG) Is Making Moderate Use Of Debt

Sep 22
Deltex Medical Group (LON:DEMG) Is Making Moderate Use Of Debt

Does Deltex Medical Group (LON:DEMG) Have A Healthy Balance Sheet?

Apr 29
Does Deltex Medical Group (LON:DEMG) Have A Healthy Balance Sheet?

CEO Compensation Analysis

How has Andy Mears's remuneration changed compared to Deltex Medical Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-UK£1m

Mar 31 2024n/an/a

-UK£1m

Dec 31 2023UK£191kUK£175k

-UK£1m

Sep 30 2023n/an/a

-UK£1m

Jun 30 2023n/an/a

-UK£1m

Mar 31 2023n/an/a

-UK£1m

Dec 31 2022UK£216kUK£200k

-UK£1m

Sep 30 2022n/an/a

-UK£1m

Jun 30 2022n/an/a

-UK£1m

Mar 31 2022n/an/a

-UK£1m

Dec 31 2021UK£216kUK£200k

-UK£966k

Sep 30 2021n/an/a

-UK£850k

Jun 30 2021n/an/a

-UK£735k

Mar 31 2021n/an/a

-UK£760k

Dec 31 2020UK£219kUK£200k

-UK£785k

Sep 30 2020n/an/a

-UK£624k

Jun 30 2020n/an/a

-UK£464k

Mar 31 2020n/an/a

-UK£311k

Dec 31 2019UK£183kUK£170k

-UK£159k

Sep 30 2019n/an/a

-UK£249k

Jun 30 2019n/an/a

-UK£339k

Mar 31 2019n/an/a

-UK£801k

Dec 31 2018UK£147kUK£77k

-UK£1m

Compensation vs Market: Andy's total compensation ($USD234.33K) is below average for companies of similar size in the UK market ($USD346.86K).

Compensation vs Earnings: Andy's compensation has been consistent with company performance over the past year.


CEO

Andy Mears (55 yo)

6.6yrs

Tenure

UK£190,500

Compensation

Mr. Andrew Jonathan Mears, also known as Andy, has been Chief Executive Officer and Director of Deltex Medical Group plc since June 13, 2018. Mr. Mears was Managing Director of Deltex Medical Group plc sin...


Leadership Team

NamePositionTenureCompensationOwnership
Andrew Mears
CEO & Director6.6yrsUK£190.50k0.61%
£ 9.3k
Natalie Wettler
Group Finance Director3.7yrsUK£128.92k0.053%
£ 808.3
Donna Connolly
Vice President of Human Resource10.2yrsno datano data

6.6yrs

Average Tenure

Experienced Management: DEMG's management team is seasoned and experienced (6.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Andrew Mears
CEO & Director6.6yrsUK£190.50k0.61%
£ 9.3k
Natalie Wettler
Group Finance Director4yrsUK£128.92k0.053%
£ 808.3
Nigel Keen
Independent Chairman29yrsUK£33.33k18.7%
£ 283.7k
Christopher Jones
Senior Independent Non-Executive Director9.6yrsUK£24.00k1.09%
£ 16.5k
Benjamin Carswell
Independent Non-Executive Director1.1yrsUK£1.50kno data

6.6yrs

Average Tenure

55yo

Average Age

Experienced Board: DEMG's board of directors are considered experienced (6.6 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/09 11:36
End of Day Share Price 2025/01/09 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Deltex Medical Group plc is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew SimmsArden Partners Plc.
Francesco GregoriCharles Stanley & Co. Ltd.
Francesco GregoriCharles Stanley Securities